Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Founded in 2000, Protiva Biotherapeutics Inc. is focused on the development of nucleic acid based pharmaceutical products to fight serious human diseases, such as cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. Validated in human clinical trials, Protiva’s proprietary Stable Nucleic-Acid Lipid Particle (SNALP) technology is an encapsulation and delivery system for nucleic acid payloads, such as short interfering RNA (siRNA), aptamers, and plasmid DNA, to target cells. It represents a breakthrough in the field of RNA interference. On July 13, 2006, Protiva announced the successful completion of a convertible debenture financing with commitments of CAD$5.6 ( www.protivabio.com )
Protiva Biotherapeutics Inc.
100-3480 Gilmore Way
Burnaby, British Columbia V5G 4Y1
Canada
Tel: (604) 630-5061
Fax: (604) 630-5103